DaVita Inc.

DVA trades at 13.4x earnings while sitting at its 52-week high—a contradictory signal that suggests either justified optimism or complacency about valuation. The 17.1% short float is substantial, indicating meaningful skepticism from bears, yet RSI at 58.3 shows momentum without overextension. For a $10B healthcare services player, this valuation sits below many peers, implying the market may be pricing in execution risk or sector headwinds. The confluence of elevated price, moderate short interest, and reasonable multiples creates an ambiguous setup where either conviction could suddenly tested; the shorts haven't capitulated, but neither has the stock broken decisively higher.